Le Lézard
Classified in: Health, Science and technology, Covid-19 virus
Subject: FEA

Apollo Hospitals' Project Kavach innovations are published in the NEJM Catalyst


HYDERABAD, India, Feb. 25, 2021 /PRNewswire/ -- Apollo Hospitals, India's largest integrated healthcare chain announced in March 2020, its campaign of Project Kavach, a multi-pronged strategy deployed to curb the COVID-19 pandemic in India. Kavach, which translates to 'shield', encompassed a 360-degree approach. 

Apollo Hospitals

The innovations pioneered by Project Kavach are highlighted in a February 24, 2021 report in the NEJM Catalyst. NEJM Catalyst is a leading American journal from the prestigious NEJM Group, focusing on the latest innovations, big ideas, and practical solutions for health care delivery transformation.

The Project Kavach commentary sheds light on the unique strategies undertaken by Apollo Hospitals such as the AI-based COVID-19 screener, which saw over 15 million downloads and adaptations in 6 regional languages, 24/7 app-based teleconsultations, doorstep testing, medication delivery across the length and breadth of the country, and remote monitoring services at home. 

Authors of the Commentary were Drs. Anupam Sibal, Hariprasad, and Sangita Reddy from Apollo Hospitals, and Professor Murali Doraiswamy from Duke University School of Medicine.  Dr. Doraiswamy is also a board member at Apollo. 

Dr. Sangita Reddy, Joint Managing Director, Apollo Hospitals, remarked, "To meet the challenges that COVID-19 threw, an integrated approach that deployed the whole Apollo ecosystem was designed. Dissemination of accurate information, early detection and isolation and tech-enabled care in different settings with advanced treatment using the best medical global protocols formed the pillars. With hospitals across 16 states, we provided care to patients in full compliance with advisories issued by different state governments. An innovative approach allowed the launch of ideas like Project Stay-I (Stay Isolated) allowing infected individuals to stay in hotels freeing up beds in hospitals. Care was provided using telemedicine. The initiative served over 80,000 nights and touched over 5 million lives over the period." 

Dr Hariprasad President, Apollo Hospitals Group noted that, "Apollo's Project Kavach has delivered exemplary results in terms of combating the COVID-19 pandemic with a phenomenal success rate. Whether it was dedicating the 2,250 beds for exclusive Covid care or setting up over 30 fever clinics, we have always led from the front. Our expertise in handling and managing Covid patients was collated and circulated in a comprehensive SOP driven guidebook called 'The Red Book' in order to help other healthcare institutions to learn from our clinical expertise." 

Dr Anupam Sibal, Group Medical Director, Apollo Hospitals, commented, "The multidisciplinary approach of bringing experts from across the Group on a virtual platform provided us with the ability to create clinical guidelines which were modified regularly, as evidence emerged. The guidelines were changed 34 times including twice in a week when data on the benefit of steroids was published. The active participation in multinational clinical trials allowed patients access to novel therapeutic options".

Dr Murali Doraiswamy, Professor of Psychiatry and Medicine, Duke University School of Medicine, USA observed that, "India's handling of COVID-19 has drawn praise globally. India deployed an approach in establishing close collaboration between the public and private sector. Project Kavach showed how the largest Indian private healthcare provider scaled their response and offer many insights and innovative solutions that can be implemented across geographies."

The full report titled, "Apollo Hospitals and Project Kavach: Insights from How India's Largest Private Health System Is Handling Covid-19", can be accessed at the link be accessed on the link below: https://catalyst.nejm.org/doi/full/10.1056/CAT.20.0677 

Contacts:

Saurabh Bose,
[email protected]

 

SOURCE Apollo Hospitals


These press releases may also interest you

at 02:15
Announces co-exclusive licensing agreement with Sanofi to co-commercialize COVID-19 vaccine, develop novel COVID-19-Influenza combination vaccines and develop multiple new vaccines utilizing Novavax's Matrix-MTM adjuvantThis agreement represents a...

at 02:05
Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter "Shionogi") and Maze Therapeutics, Inc. (Head Office: South San Francisco, California, USA; Chief Executive Officer: Jason Coloma, Ph.D.;...

at 02:00
Agreement provides individuals with broader access to a protein-based non-mRNA adjuvanted COVID-19 vaccine through combined commercial strength, from 2025 onwardsProvides Novavax with cash and an equity investment totalling approximately $1.2 billion...

at 01:00
REGULATED INFORMATIONMay 10, 2024, 7:00am CET / 1:00am ET NYXOAH SA(Euronext Brussels: NYXH) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium(hereinafter the "Company") Invitation to attend the annual and the extraordinary shareholders'...

at 00:16
WestGene, a biotech company dedicated to mRNA technology, announces a historic milestone with the FDA IND approval of its mRNA therapeutic cancer vaccine, WGc-043. This landmark achievement marks the world's first approval of an EB virus-related mRNA...

at 00:00
SN Bioscience Co. Ltd. (CEO Park Young-hwan) announced on May 7 that the FDA has granted Fast Track Designation for small cell lung cancer (SCLC) for SNB-101 (API: SN-38), a new drug for polymer nanoparticle anticancer under clinical trial. SNB-101...



News published on and distributed by: